Figure - available from: Journal of Clinical Medicine
This content is subject to copyright.
Flowchart for FAERS data processing.

Flowchart for FAERS data processing.

Source publication
Article
Full-text available
Objective: This study aimed to assess the potential of PARP inhibitors to prevent cardiotoxicity. Methods: First, a re-analysis and update of a previously published study was conducted. Additional searches were conducted of the PubMed and Cochrane Central Register of Controlled Trials databases on 2 June 2023. After the selection process, the poole...

Similar publications

Article
Full-text available
Background: Triple-negative breast cancer (TNBC) remains a clinically challenging subtype due to its aggressive nature and limited treatment options post-neoadjuvant failure. Historically, capecitabine has been the cornerstone of adjuvant therapy for TNBC patients not achieving a pathological complete response (pCR). However, the integration of new...
Article
Full-text available
Background Genetic studies of ovarian cancer (OC) have historically focused on BRCA1/2 mutations, lacking other studies of homologous recombination repair (HRR). Poly (ADP-ribose) polymerase inhibitors (PARPi) exploit synthetic lethality to significantly improve OC treatment outcomes, especially in BRCA1/2 deficiency patients. Objectives Our study...
Article
Full-text available
53BP1 nucleates the anti-end resection machinery at DNA double-strand breaks, thereby countering BRCA1 activity. Loss of 53BP1 leads to DNA end processing and homologous recombination in BRCA1-deficient cells. Consequently, BRCA1-mutant tumors, typically sensitive to PARP inhibitors (PARPi), become resistant in the absence of 53BP1. Here, we demons...
Article
Full-text available
Although the intervention for triple-negative breast cancer (TNBC) patients has improved and survival time has increased, the combination of immune checkpoint inhibitors(ICIs) and PARP inhibitors (Poly ADP-Ribose Polymerase inhibitors, PARPis) is still controversial. Previous studies revealed that the combined use of ICIs and PARPis led to increase...
Article
Full-text available
Poly(ADP-ribose) polymerases (PARPs) are key enzymes in the DNA repair pathway. Inhibitors of these enzymes belong to a new type of anticancer drugs that selectively kill cancer cells by targeting the homologous recombination genetic defects. This study presents a new synthetic approach to PARP inhibitors containing a 4-trifluoromethyl substituted...

Citations

... However, niraparib demonstrates an increased risk of hypertension and atrial flutter, which necessitates close monitoring of blood pressure and heart rhythm disturbances during treatment. When combined with antiandrogens, the risk of cardiac AEs increases; however, these agents are also associated with decreased cardiac AEs when administered in combination with chemotherapy/bevacizumab [23]. While having some cardioprotective effect, other studies have shown these drugs to be linked to major adverse cardiac events, with an incidence of 17.5% for hypertension [24]. ...
Article
Full-text available
Background/Objectives: Several drugs used to treat prostate cancer have been reported to cause cardiovascular adverse events, and this study sought to identify the real-world risk. Methods: This study utilized real-world data from the FAERS to analyze the association between prostate cancer treatment and cardiovascular adverse events. It evaluated men treated with LHRH agonists and antagonists, antiandrogens, androgen synthesis inhibitors, and PARP inhibitors from 2003 to 2023. This study included patients treated with leuprolide, goserelin, triptorelin, degarelix, relugolix, bicalutamide, flutamide, apalutamide, nilutamide, abiraterone, enzalutamide, olaparib, rucaparib, talazoparib, and niraparib. The main outcome measure was the reported odds ratio (ROR) of adverse cardiovascular event associated with these treatments. Results: Among the 4,049,329 unique adverse event reports, 4391 cardiovascular events were identified. Leuprolide (ROR 0.481, 95% CI: 0.423-0.547), triptorelin (ROR 0.527, 95% CI: 0.305-0.909), enzalutamide (ROR 0.393, 95% CI: 0.341-0.452), and olaparib (ROR 0.145, 95% CI: 0.054-0.386) reduced the risk of myocardial infarction. Goserelin increased the risk of myocardial infarction (ROR 2.235, 95% CI: 1.367-3.654). Degarelix and relugolix both increased the risk of heart failure (ROR 3.136, 95% CI: 2.186-4.497), and enzalutamide was associated with an increased risk of heart failure (ROR 1.305, 95% CI: 1.135-1.501). Bicalutamide increased the risk of unstable angina (ROR 3.019, 95% CI: 1.621-5.622) and heart failure (ROR 3.730, 95% CI: 3.085-4.510). Niraparib increased the risk of hypertension (ROR 4.154, 95% CI: 1.709-10.092). Conclusions: These findings underscore the need for clinicians to monitor cardiac complications in patients undergoing these therapies.